BlackRock’s Aegerion Pharmaceuticals AEGR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2016
Q4 | – | Sell |
-29,882
| Closed | -$89K | – | 3866 |
|
|
2016
Q3 | $89K | Sell |
29,882
-92
| -0.3% | -$159 | ﹤0.01% | 2672 |
|
|
2016
Q2 | $45K | Buy |
29,974
+28,796
| +2,444% | +$65.9K | ﹤0.01% | 2993 |
|
|
2016
Q1 | $4K | Sell |
1,178
-6,060
| -84% | -$37.5K | ﹤0.01% | 3397 |
|
|
2015
Q4 | $73K | Buy |
7,238
+6,400
| +764% | +$77K | ﹤0.01% | 1879 |
|
|
2015
Q3 | $12K | Hold |
838
| – | – | ﹤0.01% | 2664 |
|
|
2015
Q2 | $16K | Sell |
838
-68
| -8% | -$1.47K | ﹤0.01% | 2529 |
|
|
2015
Q1 | $24K | Hold |
906
| – | – | ﹤0.01% | 2288 |
|
|
2014
Q4 | $19K | Sell |
906
-2,383
| -72% | -$60K | ﹤0.01% | 2412 |
|
|
2014
Q3 | $110K | Buy |
3,289
+2,383
| +263% | +$74K | ﹤0.01% | 1687 |
|
|
2014
Q2 | $29K | Sell |
906
-54,009
| -98% | -$2.01M | ﹤0.01% | 2206 |
|
|
2014
Q1 | $2.54M | Buy |
54,915
+411
| +0.8% | +$24.1K | ﹤0.01% | 1000 |
|
|
2013
Q4 | $3.87M | Buy |
54,504
+53,779
| +7,418% | +$4.11M | 0.01% | 888 |
|
|
2013
Q3 | $62K | Hold |
725
| – | – | ﹤0.01% | 1775 |
|
|
2013
Q2 | $46K | Buy |
+725
| New | +$38.5K | ﹤0.01% | 1895 |
|
BlackRock's AEGR Position: Q4 2016 in Review
BlackRock sold out of Aegerion Pharmaceuticals (AEGR) in Q4 2016, closing a stake of 29,882 shares — an estimated $89K sold.
BlackRock first reported a position in AEGR in Q2 2013 and held it in 14 quarters. The position peaked at $3.87M in Q4 2013. 0 funds tracked by Wall St. Rank hold AEGR as of Q4 2016.
- BlackRock reported no remaining Aegerion Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
- BlackRock sold 29,882 Aegerion Pharmaceuticals shares in Q4 2016, an estimated $89K.
- BlackRock first reported a position in Aegerion Pharmaceuticals in Q2 2013 and held it in 14 quarters.
- BlackRock's Aegerion Pharmaceuticals position peaked at $3.87M in Q4 2013.
- 0 funds tracked by Wall St. Rank held Aegerion Pharmaceuticals as of Q4 2016.
Based on BlackRock's 13F filing for Q4 2016, filed 10 Feb 2017.